Repligen (NASDAQ:RGEN) Downgraded to Hold at ValuEngine

ValuEngine downgraded shares of Repligen (NASDAQ:RGEN) from a buy rating to a hold rating in a research note issued to investors on Wednesday morning, ValuEngine reports.

RGEN has been the topic of several other reports. Zacks Investment Research downgraded shares of Repligen from a buy rating to a hold rating in a research note on Wednesday, August 7th. Craig Hallum upped their price target on shares of Repligen from $80.00 to $108.00 and gave the stock a buy rating in a research note on Monday, August 5th. Stephens reaffirmed an overweight rating and issued a $110.00 price target on shares of Repligen in a research note on Thursday, August 22nd. HC Wainwright reaffirmed a buy rating and issued a $110.00 price target on shares of Repligen in a research note on Monday, August 12th. Finally, BidaskClub downgraded shares of Repligen from a strong-buy rating to a buy rating in a research note on Wednesday, September 11th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company has a consensus rating of Buy and an average price target of $101.17.

NASDAQ:RGEN traded up $1.05 during trading hours on Wednesday, hitting $76.44. 312,118 shares of the stock traded hands, compared to its average volume of 1,088,611. The firm has a 50 day moving average price of $85.62 and a 200 day moving average price of $76.57. The company has a current ratio of 2.25, a quick ratio of 1.88 and a debt-to-equity ratio of 0.02. Repligen has a fifty-two week low of $48.26 and a fifty-two week high of $99.25. The firm has a market cap of $3.88 billion, a price-to-earnings ratio of 104.71, a PEG ratio of 4.43 and a beta of 1.14.

Repligen (NASDAQ:RGEN) last announced its earnings results on Thursday, August 1st. The biotechnology company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.06. Repligen had a net margin of 11.42% and a return on equity of 6.92%. The company had revenue of $70.70 million for the quarter, compared to the consensus estimate of $65.47 million. During the same period in the previous year, the business earned $0.14 EPS. The company’s revenue was up 48.1% on a year-over-year basis. Research analysts predict that Repligen will post 0.97 EPS for the current year.

In other news, CEO Anthony Hunt sold 3,600 shares of the company’s stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $82.89, for a total value of $298,404.00. Following the transaction, the chief executive officer now directly owns 223,013 shares of the company’s stock, valued at $18,485,547.57. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 1.70% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of RGEN. Invesco Ltd. boosted its holdings in Repligen by 53.0% in the second quarter. Invesco Ltd. now owns 3,088,594 shares of the biotechnology company’s stock worth $265,465,000 after purchasing an additional 1,069,284 shares in the last quarter. BlackRock Inc. boosted its holdings in Repligen by 12.4% in the second quarter. BlackRock Inc. now owns 6,350,552 shares of the biotechnology company’s stock worth $545,830,000 after purchasing an additional 699,886 shares in the last quarter. Eagle Asset Management Inc. bought a new stake in Repligen in the second quarter worth $40,899,000. Carillon Tower Advisers Inc. bought a new stake in Repligen in the second quarter worth $29,287,000. Finally, Nuveen Asset Management LLC boosted its holdings in Repligen by 1,207.8% in the second quarter. Nuveen Asset Management LLC now owns 362,408 shares of the biotechnology company’s stock worth $31,149,000 after purchasing an additional 334,696 shares in the last quarter. 86.51% of the stock is currently owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Read More: What does a dividend yield signify to investors?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.